Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has told DirectorsTalk about the appointment of Nicola Massey as the new Managing Director of its Niche Pharmaceuticals Division.
As announced today, the Group has focused its operations into three divisions; Specials, Niche Pharmaceuticals and Medication Adherence. Niche Pharmaceuticals will comprise the Group’s existing Colonis, Lamda, and Pern business units. This section of Quantum’s business has grown since the time of IPO, and develops and supplies niche licenced pharmaceuticals and medical devices, provides development and regulatory services and out-licenses its products and dossiers to a wide range of potential third parties across Europe.
Nicola joins Quantum with more than 25 years of leadership experience in the pharmaceutical sector, having held global strategic and in-country operational leadership roles driving cross-functional teams to deliver successful launches across the UK and Europe. Previously, Nicola spent nine years at Shire PLC, focusing on speciality and rare diseases, most recently as UK and Ireland Country General Manager overseeing a period of rapid organic growth and multiple acquisitions. Nicola joins Quantum with a strong reputation in the industry having served on the Association of the British Pharmaceutical Industry (ABPI) Board of Management for two years, specialising in representing the interests of both companies and patients requiring access to medicines for rare and niche conditions.
Nicola Massey, Managing Director, Niche Pharmaceuticals at Quantum Pharma, said: “Quantum has already built a significant pipeline of regulated products to deliver on the next stage of its strategy. I look forward to leading the Niche Pharmaceuticals team as we build on and enhance the capabilities for successful medicine and medical device approvals and launches. I’m delighted to be joining the Group at such an exciting time and I look forward to working with my new colleagues and partners to deliver growth, both within Niche Pharmaceuticals, and across the wider Group.”
Andrew Scaife, Chief Executive of Quantum commented: “I would like to welcome Nicola to the team; her knowledge of the development process, pharmaceutical sector and her extensive experience of launching products in both the UK and in Europe will be highly beneficial to the Group. Having implemented the new divisional structure we believe that Nicola’s appointment will lay strong foundations for the development of our Niche Pharmaceuticals division as well to Quantum’s overall long-term growth.”
